Posted by Michael Wonder on 06 Dec 2022
IDEAYA Biosciences receives fast track designation for darovasertib combination therapy with crizotinib for the treatment of metastatic uveal melanoma
5 December 2022 - Fast track designation granted by US FDA for evaluation of darovasertib in combination with crizotinib in adult patients being treated for metastatic uveal melanoma.
IDEAYA Biosciences announced that the US FDA has granted fast track designation to IDEAYA's development program investigating darovasertib, a potential first in class protein kinase C inhibitor, for use in combination with crizotinib, an investigational cMET inhibitor, for the treatment of adult patients with metastatic uveal melanoma.
